Last edition
News about Global Pharma
Gilead Sciences and Kite Pharma to present new ASCO and EHA 2026 data highlighting progress in Antibody Drug Conjugates (ADCs) and CAR T-cell therapies, including updates on Trodelvy and anito-cel for difficult-to-treat cancers.
Global Pharma | 22/05/2026 | By News Bureau | 583
Emiltatug Ledadotin Wins FDA Breakthrough Tag for Adenoid Cystic Carcinoma
Emiltatug Ledadotin receives U.S. Food and Drug Administration Breakthrough Therapy designation for adenoid cystic carcinoma, a potentially innovative and differentiated Antibody Drug Conjugate (ADC) directed against B7-H4, a well-characterised target in certain cancers including ACC.
Global Pharma | 13/05/2026 | By News Bureau | 154
Onco-Innovations Subsidiary Partners with GSK on Real-World Oncology Data Research
Inka Health and GSK will collaborate to develop real-world data methodologies aimed at improving the applicability of oncology clinical trial findings across diverse patient populations and healthcare settings.
Global Pharma | 07/05/2026 | By News Bureau | 128
Cellenkos Receives US FDA IND Clearance for CK0802 Phase 1b/ 2a Trial in GVHD
The US Food and Drug Administration (FDA) clears Cellenkos Inc IND for CK0802, a first-in-class off-the-shelf Treg therapy, advancing to a phase 1b/2a trial in steroid-refractory Graft-Versus-Host Disease (GVHD).
Global Pharma | 06/05/2026 | By News Bureau | 179
Incyte Wins US FDA Approval for Jakafi XR (Ruxolitinib)
The US Food and Drug Administration (FDA) approves Incyte Corporation’s Jakafi XR (ruxolitinib), a once-daily extended-release tablet for myelofibrosis, polycythemia vera and GVHD, offering consistent day-long exposure.
Global Pharma | 02/05/2026 | By News Bureau | 271
Arrowhead Pharmaceuticals Wins Australia TGA Approval for REDEMPLO
Arrowhead Pharmaceuticals receives TGA approval for REDEMPLO (plozasiran) in Australia, the first treatment for Familial Chylomicronemia Syndrome (FCS), backed by phase 3 data showing significant triglyceride reduction and lower pancreatitis risk.
Global Pharma | 01/05/2026 | By News Bureau | 190
Center for Drug Evaluation accepts Bayer’s marketing authorisation application for FXIa inhibitor asundexian in stroke prevention, supported by phase 3 OCEANIC-STROKE data.
Global Pharma | 30/04/2026 | By News Bureau | 245
Pfizer Reaches Three Settlement Deals for VYNDAMAX
Pfizer reaches three settlement agreements for VYNDAMAX, extending US patent exclusivity to June 1, 2031, subject to the outcome of other litigation.
Global Pharma | 30/04/2026 | By News Bureau | 256
US FDA Approves Regeneron's Otarmeni, First Gene Therapy for Genetic Hearing Loss
US Food and Drug Administration (FDA) approves Regeneron’s Otarmeni, the first AAV-based gene therapy, offering a potential treatment for severe-to-profound hearing loss.
Global Pharma | 27/04/2026 | By News Bureau | 168
AbbVie Provides US Regulatory Update on TrenibotE BLA
AbbVie gets US FDA Complete Response Letter (CRL) for TrenibotE BLA tied to manufacturing processes; no new clinical studies needed.
Global Pharma | 24/04/2026 | By News Bureau | 126
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy